These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1067 related items for PubMed ID: 29037513

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Abiraterone acetate/androgen deprivation therapy combination versus docetaxel/androgen deprivation therapy combination in advanced hormone-sensitive prostate cancer: a network meta-analysis on safety and efficacy.
    Kassem L, Shohdy KS, Abdel-Rahman O.
    Curr Med Res Opin; 2018 May; 34(5):903-910. PubMed ID: 29490505
    [Abstract] [Full Text] [Related]

  • 3. Addition of Docetaxel to Androgen Deprivation Therapy for Patients with Hormone-sensitive Metastatic Prostate Cancer: A Systematic Review and Meta-analysis.
    Tucci M, Bertaglia V, Vignani F, Buttigliero C, Fiori C, Porpiglia F, Scagliotti GV, Di Maio M.
    Eur Urol; 2016 Apr; 69(4):563-573. PubMed ID: 26422676
    [Abstract] [Full Text] [Related]

  • 4. Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone-sensitive prostate cancer.
    Sathianathen NJ, Oestreich MC, Brown SJ, Gupta S, Konety BR, Dahm P, Kunath F.
    Cochrane Database Syst Rev; 2020 Dec 12; 12(12):CD013245. PubMed ID: 33314020
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Androgen Receptor Signaling Inhibitors in Addition to Docetaxel with Androgen Deprivation Therapy for Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Meta-analysis.
    Yanagisawa T, Rajwa P, Thibault C, Gandaglia G, Mori K, Kawada T, Fukuokaya W, Shim SR, Mostafaei H, Motlagh RS, Quhal F, Laukhtina E, Pallauf M, Pradere B, Kimura T, Egawa S, Shariat SF.
    Eur Urol; 2022 Dec 12; 82(6):584-598. PubMed ID: 35995644
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial.
    Chi KN, Protheroe A, Rodríguez-Antolín A, Facchini G, Suttman H, Matsubara N, Ye Z, Keam B, Damião R, Li T, McQuarrie K, Jia B, De Porre P, Martin J, Todd MB, Fizazi K.
    Lancet Oncol; 2018 Feb 12; 19(2):194-206. PubMed ID: 29326030
    [Abstract] [Full Text] [Related]

  • 11. Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis.
    Rydzewska LHM, Burdett S, Vale CL, Clarke NW, Fizazi K, Kheoh T, Mason MD, Miladinovic B, James ND, Parmar MKB, Spears MR, Sweeney CJ, Sydes MR, Tran N, Tierney JF, STOPCaP Abiraterone Collaborators.
    Eur J Cancer; 2017 Oct 12; 84():88-101. PubMed ID: 28800492
    [Abstract] [Full Text] [Related]

  • 12. Abiraterone acetate plus prednisone in non-metastatic biochemically recurrent castration-naïve prostate cancer.
    Spetsieris N, Boukovala M, Alafis I, Davis J, Zurita A, Wang X, Tu SM, Chapin BF, Aparicio A, Corn P, Wang J, Subudhi SK, Araujo J, Papadopoulos J, Pruitt L, Weldon JA, Logothetis CJ, Efstathiou E.
    Eur J Cancer; 2021 Nov 12; 157():259-267. PubMed ID: 34536949
    [Abstract] [Full Text] [Related]

  • 13. Optimizing Anticancer Therapy in Metastatic Non-Castrate Prostate Cancer: American Society of Clinical Oncology Clinical Practice Guideline.
    Morris MJ, Rumble RB, Basch E, Hotte SJ, Loblaw A, Rathkopf D, Celano P, Bangs R, Milowsky MI.
    J Clin Oncol; 2018 May 20; 36(15):1521-1539. PubMed ID: 29608397
    [Abstract] [Full Text] [Related]

  • 14. Triplet or Doublet Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients: A Systematic Review and Network Meta-analysis.
    Mandel P, Hoeh B, Wenzel M, Preisser F, Tian Z, Tilki D, Steuber T, Karakiewicz PI, Chun FKH.
    Eur Urol Focus; 2023 Jan 20; 9(1):96-105. PubMed ID: 36058809
    [Abstract] [Full Text] [Related]

  • 15. Addition of abiraterone, docetaxel, bisphosphonate, celecoxib or combinations to androgen-deprivation therapy (ADT) for metastatic hormone-sensitive prostate cancer (mHSPC): a network meta-analysis.
    Tan PS, Aguiar P, Haaland B, Lopes G.
    Prostate Cancer Prostatic Dis; 2018 Nov 20; 21(4):516-523. PubMed ID: 29875432
    [Abstract] [Full Text] [Related]

  • 16. Addition of Docetaxel to Androgen Receptor Axis-targeted Therapy and Androgen Deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer: A Network Meta-analysis.
    Roy S, Sayyid R, Saad F, Sun Y, Lajkosz K, Ong M, Klaassen Z, Malone S, Spratt DE, Wallis CJD, Morgan SC.
    Eur Urol Oncol; 2022 Oct 20; 5(5):494-502. PubMed ID: 35811293
    [Abstract] [Full Text] [Related]

  • 17. What is the optimal systemic treatment of men with metastatic, hormone-naive prostate cancer? A STOPCAP systematic review and network meta-analysis.
    Vale CL, Fisher DJ, White IR, Carpenter JR, Burdett S, Clarke NW, Fizazi K, Gravis G, James ND, Mason MD, Parmar MKB, Rydzewska LH, Sweeney CJ, Spears MR, Sydes MR, Tierney JF.
    Ann Oncol; 2018 May 01; 29(5):1249-1257. PubMed ID: 29788164
    [Abstract] [Full Text] [Related]

  • 18. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial.
    Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, Özgüroğlu M, Ye D, Feyerabend S, Protheroe A, Sulur G, Luna Y, Li S, Mundle S, Chi KN.
    Lancet Oncol; 2019 May 01; 20(5):686-700. PubMed ID: 30987939
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis.
    Botrel TE, Clark O, Lima Pompeo AC, Horta Bretas FF, Sadi MV, Ferreira U, Borges Dos Reis R.
    PLoS One; 2016 May 01; 11(6):e0157660. PubMed ID: 27308831
    [Abstract] [Full Text] [Related]

  • 20. Indirect Comparisons of Efficacy between Combination Approaches in Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Network Meta-analysis.
    Sathianathen NJ, Koschel S, Thangasamy IA, Teh J, Alghazo O, Butcher G, Howard H, Kapoor J, Lawrentschuk N, Siva S, Azad A, Tran B, Bolton D, Murphy DG.
    Eur Urol; 2020 Mar 01; 77(3):365-372. PubMed ID: 31679970
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 54.